SMN2 and spinal muscular atrophy: Clinically effective oligonucleotide reagents targeting splicing events have reached the bedside for other disorders, notably for increasing specific exon inclusion in SMN2 to treat spinal muscular atrophy (Bennett et al., 2019; Singh et al., 2017).